Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	ADC Therapeutics	Myovant Sciences	Heron Therapeutics	Harmony Biosciences	Aurinia Pharmaceuticals
Symbol	NYSE:ADCT	NYSE:MYOV	NASDAQ:HRTX	NASDAQ:HRMY	NASDAQ:AUPH
Price Information
Current Price	$21.23	$21.26	$13.85	$27.88	$11.92
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.3	1.7	1.4	1.8
Analysis Score	3.4	3.2	3.4	3.5	3.5
Community Score	3.7	2.6	2.7	2.1	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	1.7	0.8	2.5
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$48.75	$31.57	$27.50	$51.67	$28.00
% Upside from Price Target	129.63% upside	48.50% upside	98.56% upside	85.32% upside	134.90% upside
Trade Information
Market Cap	$1.46 billion	$1.94 billion	$1.41 billion	$1.59 billion	$1.53 billion
Beta	N/A	2.99	1.52	N/A	0.87
Average Volume	327,737	893,082	1,247,234	135,985	4,495,613
Sales & Book Value
Annual Revenue	$2.34 million	N/A	$145.97 million	N/A	$320,000.00
Price / Sales	625.03	N/A	9.66	N/A	4,772.51
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	N/A	($1.21) per share	$4.48 per share	N/A	$2.45 per share
Price / Book	∞	N/A	3.09	N/A	4.87
Profitability
Net Income	$-116,480,000.00	$-288,990,000.00	$-204,750,000.00	N/A	$-123,850,000.00
EPS	($2.36)	($3.37)	($2.50)	N/A	($0.89)
Trailing P/E Ratio	N/A	N/A	N/A	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	24.03	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-216.18%	N/A	-173,992.23%
Return on Equity (ROE)	N/A	N/A	-65.06%	N/A	-36.98%
Return on Assets (ROA)	N/A	-201.20%	-49.14%	N/A	-31.06%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.28%	N/A	N/A	2.04%	N/A
Current Ratio	15.55%	1.75%	3.60%	7.87%	17.23%
Quick Ratio	15.55%	1.75%	3.16%	7.80%	16.95%
Ownership Information
Institutional Ownership Percentage	40.88%	33.77%	99.01%	50.17%	51.21%
Insider Ownership Percentage	N/A	3.90%	12.85%	N/A	N/A
Miscellaneous
Employees	208	214	223	150	294
Shares Outstanding	68.89 million	91.48 million	101.83 million	56.90 million	128.12 million
Next Earnings Date	8/17/2021 (Estimated)	8/10/2021 (Estimated)	8/4/2021 (Estimated)	8/10/2021 (Estimated)	8/10/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Aurinia Pharmaceuticals (AUPH) Receives a Buy from Leerink Partners smarteranalyst.com - May 13 at 9:42 AM
	Peter Greenleaf Acquires 5,125 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock americanbankingnews.com - May 12 at 6:10 PM
	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Jill Leversage Acquires 2,500 Shares americanbankingnews.com - May 12 at 6:10 PM
	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) VP Matthew Maxwell Donley Buys 9,900 Shares americanbankingnews.com - May 12 at 5:26 PM
	-$0.33 Earnings Per Share Expected for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) This Quarter americanbankingnews.com - May 11 at 3:16 PM
	Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 10.1% Higher americanbankingnews.com - May 11 at 12:46 PM
	Aurinia Pharmaceuticals Inc. [AUPH] Stock trading around $10.15 per share: What’s Next? dbtnews.com - May 10 at 4:03 PM
	Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 8 at 6:06 PM
	Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results americanbankingnews.com - May 8 at 12:40 PM
	Aurinia Pharma EPS misses by $0.02, misses on revenue seekingalpha.com - May 8 at 8:05 AM
	Analysts Say Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Can Really Get to $35 in 12 Months marketingsentinel.com - May 7 at 3:13 PM
	Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year Low at $10.20 americanbankingnews.com - May 7 at 11:08 AM
	Oppenheimer Reaffirms Buy Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH) americanbankingnews.com - May 7 at 7:00 AM
	Aurinia: Q1 Earnings Snapshot sfgate.com - May 6 at 11:05 PM
	Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights finance.yahoo.com - May 6 at 6:05 PM
	Why Aurinia Pharmaceuticals Stock Is Crashing Today finance.yahoo.com - May 6 at 6:05 PM
	Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $12.27 americanbankingnews.com - May 6 at 1:34 PM
	Thinking about buying stock in Arlo Technologies, Evolus, Nikola Corp, Aurinia Pharmaceuticals, or Celsion Corp? benzinga.com - May 6 at 1:04 PM
	Aurinia Pharmaceuticals Inc. to Post FY2022 Earnings of ($0.45) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:AUPH) americanbankingnews.com - May 6 at 11:40 AM
	Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $12.08 americanbankingnews.com - April 30 at 10:44 AM
	Leerink Partners Stick to Their Buy Rating for Aurinia Pharmaceuticals investing.com - April 30 at 1:59 AM
	Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday americanbankingnews.com - April 29 at 8:16 AM
	Are Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Ready For A Higher Price Run? marketingsentinel.com - April 28 at 1:48 PM
	Zacks Investment Research Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Sell marketbeat.com - April 27 at 6:15 PM
	Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 5% americanbankingnews.com - April 27 at 3:46 PM
	Aurinia Pharmaceuticals Inc (AUPH) investing.com - April 25 at 12:33 PM

Date	Company	Brokerage	Action
5/14/2021	ADC Therapeutics	HC Wainwright	Lower Price Target
5/10/2021	ADC Therapeutics	Morgan Stanley	Lower Price Target
12/2/2020	ADC Therapeutics	Stifel Nicolaus	Initiated Coverage
6/9/2020	ADC Therapeutics	Cowen	Initiated Coverage
6/9/2020	ADC Therapeutics	Bank of America	Initiated Coverage
5/13/2021	Myovant Sciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target
5/3/2021	Myovant Sciences	JPMorgan Chase & Co.	Lower Price Target
2/12/2021	Myovant Sciences	SVB Leerink	Lower Price Target
1/6/2021	Myovant Sciences	The Goldman Sachs Group	Downgrade
12/21/2020	Myovant Sciences	Robert W. Baird	Boost Price Target
6/23/2020	Myovant Sciences	Evercore ISI	Boost Price Target
11/19/2019	Myovant Sciences	JMP Securities	Reiterated Rating
8/6/2020	Heron Therapeutics	Northland Securities	Initiated Coverage
5/26/2020	Heron Therapeutics	Guggenheim	Initiated Coverage
5/18/2020	Heron Therapeutics	FIX	Initiated Coverage
4/15/2020	Heron Therapeutics	Needham & Company LLC	Reiterated Rating
2/20/2020	Heron Therapeutics	Cantor Fitzgerald	Reiterated Rating
9/14/2020	Harmony Biosciences	Jefferies Financial Group	Initiated Coverage
9/14/2020	Harmony Biosciences	Piper Sandler	Initiated Coverage
5/7/2021	Aurinia Pharmaceuticals	Bloom Burton	Upgrade
5/7/2021	Aurinia Pharmaceuticals	Royal Bank of Canada	Lower Price Target
5/7/2021	Aurinia Pharmaceuticals	Oppenheimer	Reiterated Rating
6/16/2020	Aurinia Pharmaceuticals	BTIG Research	Initiated Coverage

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources